ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0838

T Cell–Specific CaMKIV Deficiency Protects Mice from Imiquimod-induced Glomerulonephritis

Milena Vukelic1, Masataka Umeda1, Andrew Ferretti2, Rhea Bhargava1, Nobuya Yoshida1 and George Tsokos3, 1Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, 2Beth Israel Deaconess Medical Center Harvard Medical School, Boston, 3Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2020

Keywords: Lupus nephritis, Mouse, T Cell

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: SLE – Animal Models Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibody production, immune complex deposition and multisystem involvement.  Calcium/calmodulin-dependent protein kinase type IV (CaMK4) is serine-threonine kinase overexpressed in SLE CD4 T cells. Global CaMK4 deficiency or inhibition with a small drug in MRL/lpr mice resulted in prolonged survival, significant suppression of proteinuria, severity of glomerulonephritis and autoantibody production. Here, we hypothesized that targeted T cell specific deletion of CaMK4 will protect mice from the development of systemic autoimmune disease induced by application of imiquimod, a toll-like receptor agonist.

Methods: We generated T cell specific CaMK4 conditionally deficient mice on C57BL/6 background by using Cre-loxP system.  Mice harboring loxP sites of Camk4 gene  ( Camk4 flox/flox) were crossed with Cre transgenic mice driven by distal Lck promoter.  Female mice were genotyped and 12 weeks old Lck-Cre positive and negative Camk4 flox/flox littermates  were used for the experiment. Mice were treated with imiquimod applied to the ears 3 times weekly for 8 weeks.  Serum, urine, kidneys and other organs were collected for the analysis. Levels of dsDNA were measured by ELISA.  Proteinuria was assessed by measuring albumin to creatinine ratio. Kidney sections were scored for damage in a blinded manner by using the renal activity index. T- test was used for statistical analysis and data are expressed as mean±SEM.

Results: Lck-Cre+ Camk4 flox/flox mice had normal development and lifespan.  We had 4 Lck-Cre Camk4 flox/flox negative and positive mice per group.  After 8 weeks of imiquimod treatment elevated levels of autoantibodies to double-stranded DNA were similar between the groups  ( Lck-Cre +/ Camk4 flox/flox :18.68±1.72 vs. Lck-Cre -/ Camk4 flox/flox 21.73± 3.34 IU /ml).  Spleen sizes were similar between the groups.  Excitingly, proteinuria was significantly decreased in Lck-Cre +/ Camk4 flox/flox mice compared to Lck-Cre negative (871.94±227.24 vs. 1437.9±275.56 mg/gr; p= 0.0023).  Histopathologic examination of the kidneys showed  that T cell specific CaMK4 deficiency in LcK-Cre positive animals significantly decreased infiltration in the kidney parenchima.

Conclusion: We have generated evidence that specific deletion of CaMKIV in T cells ameliorates severity of glomerulonephritis after the administration of the TLR7 agonist without affecting the production of antibodies to dsDNA. Our data support the development targeted delivery of a CaMK4 inhibitors to T cells for the treatment of patients with SLE.


Disclosure: M. Vukelic, None; M. Umeda, None; A. Ferretti, None; R. Bhargava, None; N. Yoshida, None; G. Tsokos, None.

To cite this abstract in AMA style:

Vukelic M, Umeda M, Ferretti A, Bhargava R, Yoshida N, Tsokos G. T Cell–Specific CaMKIV Deficiency Protects Mice from Imiquimod-induced Glomerulonephritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/t-cell-specific-camkiv-deficiency-protects-mice-from-imiquimod-induced-glomerulonephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/t-cell-specific-camkiv-deficiency-protects-mice-from-imiquimod-induced-glomerulonephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology